Key points are not available for this paper at this time.
Post-traumatic stress disorder (PTSD) is an often debilitating condition caused by a person’s exposure to traumatic events. Symptoms of PTSD include intrusive thoughts, suicidal ideation, and highly negative and distressing emotional states. Current treatments for PTSD such as cognitive behavioral therapy, EMDR, and SSRIs and SNRIs are ineffective for a large chunk of patients who seek out treatment. A majority of patients with PTSD do not respond to talking therapy, and the remission rate for patients on SSRIs and SNRIs is low. The ineffectiveness of recommended treatments has led to experimentation with drugs like MDMA. MDMA increases levels of chemicals in the brain that induce happy and calm states. This drug also decreases fear states in patients, allowing them to more comfortably discuss traumatic events without the possible side effects of extreme emotional numbness or high levels of anxiety. Research conducted in the last decade on MDMA in addition to psychotherapy in a clinical setting has yielded impressive results. A majority of patients in all three conducted trials experienced a long-term reduction in PTSD symptoms. MDMA in a clinical setting was also proven to be safe, with no serious drug-related side effects on patients. With such high rates of symptom reduction, these studies provide hope for the future of effective and safe PTSD treatment.
Panin et al. (Fri,) studied this question.